These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 38696451)

  • 61. DENVIS: Scalable and High-Throughput Virtual Screening Using Graph Neural Networks with Atomic and Surface Protein Pocket Features.
    Krasoulis A; Antonopoulos N; Pitsikalis V; Theodorakis S
    J Chem Inf Model; 2022 Oct; 62(19):4642-4659. PubMed ID: 36154119
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comprehensive Review on Drug-target Interaction Prediction - Latest Developments and Overview.
    Abdul Raheem AK; Dhannoon BN
    Curr Drug Discov Technol; 2024; 21(2):e010923220652. PubMed ID: 37680152
    [TBL] [Abstract][Full Text] [Related]  

  • 63. How are fragments optimized? A retrospective analysis of 145 fragment optimizations.
    Ferenczy GG; Keserű GM
    J Med Chem; 2013 Mar; 56(6):2478-86. PubMed ID: 23437770
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Multiple ligand detection and affinity measurement by ultrafiltration and mass spectrometry analysis applied to fragment mixture screening.
    Qin S; Ren Y; Fu X; Shen J; Chen X; Wang Q; Bi X; Liu W; Li L; Liang G; Yang C; Shui W
    Anal Chim Acta; 2015 Jul; 886():98-106. PubMed ID: 26320641
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dynamic template-assisted strategies in fragment-based drug discovery.
    Schmidt MF; Rademann J
    Trends Biotechnol; 2009 Sep; 27(9):512-21. PubMed ID: 19679363
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Advances in the discovery of new chemotypes through ultra-large library docking.
    Potlitz F; Link A; Schulig L
    Expert Opin Drug Discov; 2023 Mar; 18(3):303-313. PubMed ID: 36714919
    [TBL] [Abstract][Full Text] [Related]  

  • 67. SARS-CoV-2 Spike Protein Interaction Space.
    Lungu CN; Putz MV
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569436
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Virtual Screening Techniques and Current Computational Infrastructures.
    Haga JH; Ichikawa K; Date S
    Curr Pharm Des; 2016; 22(23):3576-84. PubMed ID: 27075580
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity.
    Weng YL; Naik SR; Dingelstad N; Lugo MR; Kalyaanamoorthy S; Ganesan A
    Sci Rep; 2021 Apr; 11(1):7429. PubMed ID: 33795718
    [TBL] [Abstract][Full Text] [Related]  

  • 70. From fragment screening to potent binders: strategies for fragment-to-lead evolution.
    Eitner K; Koch U
    Mini Rev Med Chem; 2009 Jul; 9(8):956-61. PubMed ID: 19601891
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Reaction-Based Enumeration, Active Learning, and Free Energy Calculations To Rapidly Explore Synthetically Tractable Chemical Space and Optimize Potency of Cyclin-Dependent Kinase 2 Inhibitors.
    Konze KD; Bos PH; Dahlgren MK; Leswing K; Tubert-Brohman I; Bortolato A; Robbason B; Abel R; Bhat S
    J Chem Inf Model; 2019 Sep; 59(9):3782-3793. PubMed ID: 31404495
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Graph Convolutional Capsule Regression (GCCR): A Model for Accelerated Filtering of Novel Potential Candidates for SARS-CoV-2 based on Binding Affinity.
    Krishnan A; Vinod D
    Curr Comput Aided Drug Des; 2024; 20(1):33-41. PubMed ID: 37005531
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Artificial Intelligence, Machine Learning, and Deep Learning in Real-Life Drug Design Cases.
    Muller C; Rabal O; Diaz Gonzalez C
    Methods Mol Biol; 2022; 2390():383-407. PubMed ID: 34731478
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fingerprinting Interactions between Proteins and Ligands for Facilitating Machine Learning in Drug Discovery.
    Li Z; Huang R; Xia M; Patterson TA; Hong H
    Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254672
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Merging Ligand-Based and Structure-Based Methods in Drug Discovery: An Overview of Combined Virtual Screening Approaches.
    Vázquez J; López M; Gibert E; Herrero E; Luque FJ
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33076254
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Biological activity-based modeling identifies antiviral leads against SARS-CoV-2.
    Huang R; Xu M; Zhu H; Chen CZ; Zhu W; Lee EM; He S; Zhang L; Zhao J; Shamim K; Bougie D; Huang W; Xia M; Hall MD; Lo D; Simeonov A; Austin CP; Qiu X; Tang H; Zheng W
    Nat Biotechnol; 2021 Jun; 39(6):747-753. PubMed ID: 33623157
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications.
    Bian Y; Xie XS
    AAPS J; 2018 Apr; 20(3):59. PubMed ID: 29633051
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
    Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
    Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
    [TBL] [Abstract][Full Text] [Related]  

  • 79. ES-Screen: A Novel Electrostatics-Driven Method for Drug Discovery Virtual Screening.
    Issa NT; Byers SW; Dakshanamurthy S
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499162
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Fragment-based drug discovery using rational design.
    Jhoti H
    Ernst Schering Found Symp Proc; 2007; (3):169-85. PubMed ID: 18510103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.